New Alzheimer's Drugs offer "genuine, tangible, quantifiable hope" in mild to moderate Alzheimer's

AARP's website today is announcing that there is a new generation of drug that scientists are expected to announce final test results for soon.

AARP says that one expert calls the new medicines; "genuine, tangible, quantifiable hope" for people with mild to moderate Alzheimer's.

In the article on AARP.org, Sam Gandy, M.D., chair of the National Medical and Scientific Advisory Council of the Alzheimer's Association and director of the Farber Institute for Neurosciences in Philadelphia, says, "Within three years, it's all but certain we'll have disease-modifying drugs that fundamentally change the nature of Alzheimer's."

The first new drug that test results are expected for is Alzhemed, from Neurochem.

One of the most promising is Flurizan, from Myriad Genetics, and its tests should be completed within the next 18 months.

Today, 5.1 million people in the United States have the disease. One in eight people age 65 and older now has Alzheimer's; half of those 85 and older have it.

Read the full story